Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder of angiogenesis associated
with disabling epistaxis. Management of these nose bleedings requires more effective
treatment. Propranolol, a beta-blocker, is a potentially useful therapeutic considering its
anti-angiogenic properties. Our objective is to explore the efficacy of propranolol, three
months after its introduction, on the cumulative duration of epistaxis in HHT patients.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Bordeaux
Collaborator:
AMRO-HHT-France - Association Maladie de Rendu-Osler